Inivata Email Format
Biotechnology ResearchNorth Carolina, United States51-200 Employees
Inivata develops liquid biopsy platforms that derive genomic information from a blood sample to support cancer treatment decisions. Its lead test, InVisionFirst-Lung, provides molecular insights to guide therapy for non-small cell lung cancer, while the RaDaR assay targets residual disease and relapse detection. The company collaborates with pharmaceutical and biotechnology partners to extend InVisionFirst-Lung and the broader platform across multiple cancer types. The technology has its roots in research conducted at the Cancer Research UK Cambridge Institute and the University of Cambridge, supported by publications. Based in Durham, North Carolina, with a CLIA-certified laboratory in Research Triangle Park and R&D facilities in Cambridge, United Kingdom, Inivata operates in the oncology diagnostics segment as a mid-sized biotechnology company.